Considerations for treatment of hemophilia B patients in high-risk settings are the focus of this paper, including differences in recoveries of factor IX products and variable patient responses to replacement therapy. Data support the importance of performing individual pharmacokinetic studies in determining treatment programs for hemophilia patients-for both high-risk periods such as surgery and for prophylaxis. Other considerations in choice of plasma-derived or recombinant factor IX concentrate in high-risk and other situations include product safety, cost, and availability.
|Original language||English (US)|
|Journal||Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis|
|Volume||15 Suppl 2|
|State||Published - Jan 1 2004|
ASJC Scopus subject areas